Skip to main content

Table 1 Baseline characteristics of study sample

From: Epidemiology, risk factors, and clinical impact of early post-transplant infection in older kidney transplant recipients: the Korean organ transplantation registry study

  Overall (N = 3738) <  60 year-old (n = 3081) ≥ 60 year-old (n = 657) p
Age (years) 48.78 ± 11.50 45.53 ± 9.88 64.08 ± 3.48 <  0.001
Sex, female (%) 1527 (40.9%) 1287 (41.8%) 240 (36.5%) 0.013
Body mass index (kg/m2) 23.05 ± 3.52 22.97 ± 3.61 23.41 ± 3.05 0.001
Cause of ESRD, n (%)     <  0.001
 Diabetes mellitus 870 (23.3%) 642 (20.8%) 228 (34.7%)  
 Hypertension 612 (16.4%) 486 (15.8%) 126 (19.2%)  
 Glomerulonephritis 1251 (33.5%) 1121 (36.4%) 130 (19.8%)  
 ADPKD 172 (4.6%) 137 (4.4%) 35 (5.3%)  
 Others 123 (3.3%) 103 (3.3%) 20 (3.0%)  
 Unknown 710 (19.0%) 592 (19.2%) 118 (18.0%)  
Duration of dialysis (months) 56.17 ± 64.13 47.29 ± 62.77 50.73 ± 61.03 0.201
Diabetes mellitus, n (%) 1073 (28.7%) 778 (25.3%) 295 (44.9%) <  0.001
Hypertension, n (%) 3334 (89.2%) 2719 (88.3%) 615 (93.6%) <  0.001
Cardiovascular disease, n (%) 404 (10.8%) 260 (8.4%) 144 (22.0%) <  0.001
Hemoglobin (g/dL) 10.73 ± 1.58 10.70 ± 1.59 10.88 ± 1.52 0.006
Creatinine, baseline (mg/dL) 8.79 ± 3.36 8.96 ± 3.42 8.01 ± 2.98 <  0.001
Creatinine, discharge (mg/dL) 1.22 ± 0.78 1.22 ± 0.79 1.21 ± 0.69 0.708
Albumin (g/dL) 3.93 ± 0.52 3.93 ± 0.53 3.89 ± 0.49 0.049
Re-transplantation, n (%) 289 (7.7%) 249 (8.1%) 40 (6.1%) 0.082
Donor age (years) 46.44 ± 13.18 45.47 ± 12.78 50.95 ± 14.05 <  0.001
Donor sex, female (%) 1720 (46.0%) 1437 (46.7%) 283 (43.1%) 0.095
Deceased donor, n (%) 1446 (38.7%) 1111 (36.1%) 335 (51.0%) <  0.001
Desensitization, n (%) 845 (22.6%) 723 (23.5%) 122 (18.6%) 0.006
ABO incompatibility, n (%) 586 (15.7%) 495 (16.1%) 91 (13.9%) 0.156
Presence of DSA, n (%) 230 (6.2%) 184 (6.0%) 46 (7.0%) 0.319
Length of hospitalization after KT (days) 17.88 ± 10.63 17.53 ± 10.35 19.56 ± 11.71 <  0.001
Induction immunosuppression     <  0.001
No use, n (%) 66 (1.8%) 52 (1.7%) 14 (2.1%)  
 Basiliximab, n (%) 2924 (78.2%) 2447 (79.4%) 477 (72.8%)  
 ATG, n (%) 668 (17.9%) 513 (16.7%) 155 (23.7%)  
 Basiliximab + ATG, n (%) 77 (2.1%) 68 (2.2%) 9 (1.4%)  
Calcineurin inhibitors, n (%)     0.067
 No use 45 (1.2%) 32 (1.0%) 13 (2.0%)  
 Tacrolimus 3568 (95.5%) 2952 (95.8%) 616 (94.0%)  
 Cyclosporine 122 (3.3%) 96 (3.1%) 26 (4.0%)  
Mycophenolate, n (%) 3399 (90.9%) 2819 (91.5%) 580 (88.7%) 0.021
mTOR inhibitors, n (%) 48 (1.3%) 37 (1.2%) 11 (1.7%) 0.324
Steroid, n (%) 3647 (97.6%) 3011 (97.2%) 636 (97.2%) 0.430
Follow-up duration (months) 27.45 ± 12.47 27.95 ± 12.41 25.14 ± 12.49 <  0.001
Early post-transplant infection, n (%) 670 (17.9%) 521 (16.9%) 149 (22.7%) <  0.001
  1. ESRD end stage renal disease, ADPKD autosomal dominant polycystic kidney disease, DSA donor specific antibody, KT kidney transplantation, ATG anti-thymocyte globulin